Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer.
10.3779/j.issn.1009-3419.2021.101.46
- Author:
Xinlong LIU
1
,
2
;
Teng SUN
1
,
2
;
Tao HONG
1
,
2
;
Yanliang YUAN
1
,
2
;
Hao ZHANG
1
,
2
Author Information
1. Department of Thoracic Surgery, Affiliated Hospital of Xuzhou Medical University
2. Thoracic Surgery Laboratory, The First College of Clinical Medicine, Xuzhou Medical University, Xuzhou 221006, China.
- Publication Type:Journal Article
- Keywords:
Bronchial sleeve resection;
Central lung cancer;
Da Vinci Xi robot system;
Lung neoplasms;
Neoadjuvant immunotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/surgery*;
Humans;
Lung Neoplasms/surgery*;
Neoadjuvant Therapy;
Pneumonectomy/methods*;
Retrospective Studies;
Robotics;
Thoracotomy;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2022;25(2):71-77
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Immunoneoadjuvant therapy opens a new prospect for local advanced lung cancer. The aim of our study was to explore the safety and feasibility of robotic-assisted bronchial sleeve resection in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy.
METHODS:Data of 13 patients with locally advanced NSCLC that underwent bronchial sleeve resection after neoadjuvant chemoimmunotherapy during August 2020 and February 2021 were retrospectively included. According to the surgical methods, patients were divided into thoracotomy bronchial sleeve resection (TBSR) group and robot-assisted bronchial sleeve resection (RABSR) group. Oncology, intraoperative, and postoperative data in the two groups were compared.
RESULTS:The two groups of patients operated smoothly, the postoperative pathology confirmed that all the tumor lesions achieved R0 resection, and RABSR group no patient was transferred to thoracotomy during surgery. Partial remission (PR) rate and major pathological remissions (MPR) rate of patients in the TBSR group were 71.43% and 42.86%, respectively. Complete pathological response (pCR) was 28.57%. They were 66.67%, 50.00% and 33.33% in RABSR group, respectively. There were no significant differences in operative duration, number of lymph nodes dissected, intraoperative blood loss, postoperative drainage time and postoperative hospital stay between the two groups, but the bronchial anastomosis time of RABSR group was relatively short. Both groups of patients had a good prognosis. Successfully discharged from the hospital and post-operative 90-d mortality rate was 0.
CONCLUSIONS:In patients with locally advanced central NSCLC after neoadjuvant chemoimmunotherapy can achieve the tumor reduction, tumor stage decline and increase the R0 resection rate, bronchial sleeve resection is safe and feasible. Under the premise of following the two principles of surgical safety and realizing the tumor R0 resection, robot-assisted bronchial sleeve resection can be preferred.
